IL311711A - Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors - Google Patents
Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitorsInfo
- Publication number
- IL311711A IL311711A IL311711A IL31171124A IL311711A IL 311711 A IL311711 A IL 311711A IL 311711 A IL311711 A IL 311711A IL 31171124 A IL31171124 A IL 31171124A IL 311711 A IL311711 A IL 311711A
- Authority
- IL
- Israel
- Prior art keywords
- arhgef12
- glaucoma
- inhibitors
- treatment
- guanine nucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250492P | 2021-09-30 | 2021-09-30 | |
| PCT/US2022/077176 WO2023056295A1 (en) | 2021-09-30 | 2022-09-28 | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311711A true IL311711A (en) | 2024-05-01 |
Family
ID=83996920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311711A IL311711A (en) | 2021-09-30 | 2022-09-28 | Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12577562B2 (https=) |
| EP (1) | EP4408535A1 (https=) |
| JP (1) | JP2024535110A (https=) |
| KR (1) | KR20240099232A9 (https=) |
| CN (1) | CN118891050A (https=) |
| AU (1) | AU2022357497A1 (https=) |
| CA (1) | CA3232251A1 (https=) |
| IL (1) | IL311711A (https=) |
| WO (1) | WO2023056295A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7972612B2 (en) | 2002-11-18 | 2011-07-05 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
| US20090264533A1 (en) * | 2005-03-30 | 2009-10-22 | Richard Neubig | Methods and Compositions for Modulating RHO-Mediated Gene Transcription |
| AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| GB201107176D0 (en) * | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
| EP3866790A4 (en) | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| JP2022523301A (ja) * | 2019-01-23 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
-
2022
- 2022-09-28 EP EP22797214.8A patent/EP4408535A1/en active Pending
- 2022-09-28 WO PCT/US2022/077176 patent/WO2023056295A1/en not_active Ceased
- 2022-09-28 CN CN202280075189.3A patent/CN118891050A/zh active Pending
- 2022-09-28 KR KR1020247014295A patent/KR20240099232A9/ko active Pending
- 2022-09-28 CA CA3232251A patent/CA3232251A1/en active Pending
- 2022-09-28 US US17/936,244 patent/US12577562B2/en active Active
- 2022-09-28 JP JP2024519586A patent/JP2024535110A/ja active Pending
- 2022-09-28 IL IL311711A patent/IL311711A/en unknown
- 2022-09-28 AU AU2022357497A patent/AU2022357497A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4408535A1 (en) | 2024-08-07 |
| AU2022357497A1 (en) | 2024-04-04 |
| US12577562B2 (en) | 2026-03-17 |
| US20230099109A1 (en) | 2023-03-30 |
| JP2024535110A (ja) | 2024-09-26 |
| WO2023056295A1 (en) | 2023-04-06 |
| CA3232251A1 (en) | 2023-04-06 |
| CN118891050A (zh) | 2024-11-01 |
| KR20240099232A9 (ko) | 2025-12-10 |
| KR20240099232A (ko) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100028I1 (hu) | ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére | |
| US20140206639A1 (en) | Uses of dihydro bases | |
| EP4315015A4 (en) | Write bank group mask during arbitration | |
| NZ598242A (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| ZA202503575B (en) | Novel prmt5 inhibitor and use thereof | |
| WO2013040528A1 (en) | Antimicrobial compounds | |
| PL2250172T3 (pl) | Pirolopirazynowe inhibitory kinazy | |
| AU2014268477A1 (en) | Compounds for treatment of drug resistant and persistent tuberculosis | |
| ATE495173T1 (de) | Kinase-inhibitoren | |
| CY1116043T1 (el) | Κρυσταλλικες μορφες υδροχλωρικου αλατος (4α-r,9α-s)-1-(1η-βενζοϊμιδαζολο-5-καρβονυλ)2,3,4,4α,9,9α-εξαϋδρο-1η-ινδενο[2,1-β]πυριδινο-6-καρβονιτριλιου και χρηση τους ως αναστολεις της hsd 1 | |
| MX2021001503A (es) | Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico. | |
| IL311711A (en) | Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors | |
| EP4138842A4 (en) | METHODS OF USING RHO-KINASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| HK40113128A (en) | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors | |
| Mittal et al. | Identification of tissue‐preferential expression patterns of rice miRNAs | |
| Tunçbilek et al. | Synthesis and antimicrobial evaluation of some new substituted purine derivatives | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. | |
| HK1212212A1 (en) | Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors | |
| MX2026000476A (es) | Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa | |
| CL2025003529A1 (es) | Nuevos polimorfos de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma cristalina. | |
| BRPI0508927A (pt) | compostos úteis para o tratamento de doenças | |
| US20220098208A1 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
| BR112023019582A2 (pt) | Oligonucleotídeo antissenso inibidor de microrna-27b | |
| MY197850A (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
| EP3476939A4 (en) | NUCLEIC ACID FOR INHIBITING THE EXPRESSION OF THE MEX3B GENE, MEX3B GENE EXPRESSION INHIBITOR, METHOD FOR INHIBITING MEX3B GENE EXPRESSION, PROPHYLACTIC ACID OR THERAPEUTIC FOR DISEASES THROUGH MEX3B GENE EXPRESSION |